[The application of hematopoietic growth factors in oncology]

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial.

Leukemia·2024

Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.

Leukemia·2022

Evaluating ivosidenib for the treatment of acute myeloid leukemia.

Expert opinion on pharmacotherapy·2020

Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS.

Leukemia·2020

Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS.

Leukemia·2020

Improved survival for children and young adolescents with acute myeloid leukemia: a Dutch study on incidence, survival and mortality.

Leukemia·2018

[Epstein-Barr virus infection; many clinical pictures, often relevant to consider].

Nederlands tijdschrift voor geneeskunde·2026

[Fitness to drive].

Nederlands tijdschrift voor geneeskunde·2026

[Selection of trainees for medical specialties; time for a different approach].

Nederlands tijdschrift voor geneeskunde·2026

[A young woman with a tumor on the finger].

Nederlands tijdschrift voor geneeskunde·2026

[A new era in the treatment ofStaphylococcus aureusbacteremia: cefazolin becomes first choice].

Nederlands tijdschrift voor geneeskunde·2026

[Marchiafava-Bignami disease: an alcoholic with reduced consciousness and muscle paratonia].

Nederlands tijdschrift voor geneeskunde·2026

Co-occurrence of GATA2 deficiency and probable constitutional mosaic STAG2 alteration in a young adult with myelodysplastic syndrome: a case report.

Frontiers in medicine·2026

Epstein-Barr virus reactivation and post-transplant lymphoproliferative disease risk deserve a place in the JAK inhibitor toxicity profile. Comment on: "Janus kinase inhibitors as an evolving treatment for lymphomas and immune-mediated complications".

Haematologica·2026

Venous Thromboembolism in Patients Treated with Everolimus: Insights from a Case Series and the French Pharmacovigilance Database.

Current vascular pharmacology·2026

Hepatocellular Carcinoma With JAK1 Mutations Harbors Distinct Histologic Features and Specific Mutational Hotspots in an Asian Cohort.

The American journal of surgical pathology·2026

TH/TRs-COL11A2 Axis Mediates Loss of a Differentiated Astrocyte State in Hypogyrified Brains.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Functional contribution of Epstein-Barr virus BARF1 residues 35-39 to viable cell maintenance under serum deprivation and tumor formation.

Virus genes·2026

Related Experiment Videos

[The application of hematopoietic growth factors in oncology]

Related Concept Videos

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial.

Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.

Evaluating ivosidenib for the treatment of acute myeloid leukemia.

Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS.

Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS.

Improved survival for children and young adolescents with acute myeloid leukemia: a Dutch study on incidence, survival and mortality.

[Epstein-Barr virus infection; many clinical pictures, often relevant to consider].

[Fitness to drive].

[Selection of trainees for medical specialties; time for a different approach].

[A young woman with a tumor on the finger].

[A new era in the treatment ofStaphylococcus aureusbacteremia: cefazolin becomes first choice].

[Marchiafava-Bignami disease: an alcoholic with reduced consciousness and muscle paratonia].

Co-occurrence of GATA2 deficiency and probable constitutional mosaic STAG2 alteration in a young adult with myelodysplastic syndrome: a case report.

Epstein-Barr virus reactivation and post-transplant lymphoproliferative disease risk deserve a place in the JAK inhibitor toxicity profile. Comment on: "Janus kinase inhibitors as an evolving treatment for lymphomas and immune-mediated complications".

Venous Thromboembolism in Patients Treated with Everolimus: Insights from a Case Series and the French Pharmacovigilance Database.

Hepatocellular Carcinoma With JAK1 Mutations Harbors Distinct Histologic Features and Specific Mutational Hotspots in an Asian Cohort.

TH/TRs-COL11A2 Axis Mediates Loss of a Differentiated Astrocyte State in Hypogyrified Brains.

Functional contribution of Epstein-Barr virus BARF1 residues 35-39 to viable cell maintenance under serum deprivation and tumor formation.

Related Experiment Videos

[The application of hematopoietic growth factors in oncology]

Related Concept Videos

Related Articles